nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—SLC6A4—epilepsy syndrome	0.295	1	CbGaD
Sibutramine—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0264	0.0879	CbGbCtD
Sibutramine—CYP3A4—Felbamate—epilepsy syndrome	0.0245	0.0817	CbGbCtD
Sibutramine—CYP3A4—Trimethadione—epilepsy syndrome	0.0245	0.0817	CbGbCtD
Sibutramine—CYP3A4—Fosphenytoin—epilepsy syndrome	0.023	0.0768	CbGbCtD
Sibutramine—CYP3A4—Clonazepam—epilepsy syndrome	0.0208	0.0694	CbGbCtD
Sibutramine—CYP3A4—Clobazam—epilepsy syndrome	0.02	0.0666	CbGbCtD
Sibutramine—CYP3A4—Rufinamide—epilepsy syndrome	0.017	0.0566	CbGbCtD
Sibutramine—CYP3A4—Carbamazepine—epilepsy syndrome	0.0166	0.0552	CbGbCtD
Sibutramine—CYP3A4—Primidone—epilepsy syndrome	0.0155	0.0515	CbGbCtD
Sibutramine—CYP3A4—Phenytoin—epilepsy syndrome	0.0148	0.0495	CbGbCtD
Sibutramine—CYP3A4—Propofol—epilepsy syndrome	0.0138	0.0462	CbGbCtD
Sibutramine—CYP3A4—Acetazolamide—epilepsy syndrome	0.0132	0.0441	CbGbCtD
Sibutramine—CYP3A4—Phenobarbital—epilepsy syndrome	0.0132	0.0441	CbGbCtD
Sibutramine—CYP3A4—Midazolam—epilepsy syndrome	0.013	0.0435	CbGbCtD
Sibutramine—CYP3A4—Diazepam—epilepsy syndrome	0.0125	0.0418	CbGbCtD
Sibutramine—CYP3A4—Zonisamide—epilepsy syndrome	0.0122	0.0408	CbGbCtD
Sibutramine—CYP3A4—Valproic Acid—epilepsy syndrome	0.00989	0.033	CbGbCtD
Sibutramine—CYP3A4—Topiramate—epilepsy syndrome	0.00892	0.0297	CbGbCtD
Sibutramine—SLC6A2—locus ceruleus—epilepsy syndrome	0.00751	0.157	CbGeAlD
Sibutramine—SLC6A3—telencephalic ventricle—epilepsy syndrome	0.00441	0.0923	CbGeAlD
Sibutramine—SLC6A2—autonomic nervous system—epilepsy syndrome	0.00399	0.0835	CbGeAlD
Sibutramine—SLC6A3—ganglion—epilepsy syndrome	0.00275	0.0575	CbGeAlD
Sibutramine—SLC6A4—ganglion—epilepsy syndrome	0.00252	0.0527	CbGeAlD
Sibutramine—SLC6A2—ganglion—epilepsy syndrome	0.00222	0.0464	CbGeAlD
Sibutramine—SLC6A3—hindbrain—epilepsy syndrome	0.00208	0.0436	CbGeAlD
Sibutramine—SLC6A4—hindbrain—epilepsy syndrome	0.00191	0.0399	CbGeAlD
Sibutramine—SLC6A3—brainstem—epilepsy syndrome	0.00119	0.025	CbGeAlD
Sibutramine—SLC6A3—forebrain—epilepsy syndrome	0.00115	0.0241	CbGeAlD
Sibutramine—SLC6A4—brainstem—epilepsy syndrome	0.00109	0.0229	CbGeAlD
Sibutramine—SLC6A3—telencephalon—epilepsy syndrome	0.00106	0.0222	CbGeAlD
Sibutramine—SLC6A4—forebrain—epilepsy syndrome	0.00106	0.0221	CbGeAlD
Sibutramine—SLC6A4—telencephalon—epilepsy syndrome	0.000971	0.0203	CbGeAlD
Sibutramine—SLC6A2—brainstem—epilepsy syndrome	0.000964	0.0202	CbGeAlD
Sibutramine—SLC6A2—forebrain—epilepsy syndrome	0.00093	0.0195	CbGeAlD
Sibutramine—SLC6A2—telencephalon—epilepsy syndrome	0.000855	0.0179	CbGeAlD
Sibutramine—SLC6A3—midbrain—epilepsy syndrome	0.000761	0.0159	CbGeAlD
Sibutramine—SLC6A3—spinal cord—epilepsy syndrome	0.000743	0.0155	CbGeAlD
Sibutramine—SLC6A4—midbrain—epilepsy syndrome	0.000698	0.0146	CbGeAlD
Sibutramine—SLC6A4—spinal cord—epilepsy syndrome	0.000681	0.0142	CbGeAlD
Sibutramine—SLC6A2—medulla oblongata—epilepsy syndrome	0.000672	0.0141	CbGeAlD
Sibutramine—SLC6A3—head—epilepsy syndrome	0.00066	0.0138	CbGeAlD
Sibutramine—SLC6A3—nervous system—epilepsy syndrome	0.000626	0.0131	CbGeAlD
Sibutramine—SLC6A4—head—epilepsy syndrome	0.000605	0.0127	CbGeAlD
Sibutramine—SLC6A3—central nervous system—epilepsy syndrome	0.000602	0.0126	CbGeAlD
Sibutramine—SLC6A3—cerebellum—epilepsy syndrome	0.000589	0.0123	CbGeAlD
Sibutramine—SLC6A4—nervous system—epilepsy syndrome	0.000573	0.012	CbGeAlD
Sibutramine—SLC6A4—central nervous system—epilepsy syndrome	0.000552	0.0115	CbGeAlD
Sibutramine—SLC6A2—head—epilepsy syndrome	0.000532	0.0111	CbGeAlD
Sibutramine—SLC6A2—nervous system—epilepsy syndrome	0.000505	0.0106	CbGeAlD
Sibutramine—SLC6A2—central nervous system—epilepsy syndrome	0.000486	0.0102	CbGeAlD
Sibutramine—SLC6A3—brain—epilepsy syndrome	0.000478	0.01	CbGeAlD
Sibutramine—SLC6A4—brain—epilepsy syndrome	0.000438	0.00917	CbGeAlD
Sibutramine—SLC6A2—brain—epilepsy syndrome	0.000386	0.00807	CbGeAlD
Sibutramine—CYP3A4—nervous system—epilepsy syndrome	0.000281	0.00588	CbGeAlD
Sibutramine—CYP3A4—central nervous system—epilepsy syndrome	0.00027	0.00566	CbGeAlD
Sibutramine—SLC6A4—Circadian rythm related genes—CHRNB2—epilepsy syndrome	0.000127	0.00184	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SLC2A1—epilepsy syndrome	0.000125	0.00181	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—STXBP1—epilepsy syndrome	0.000125	0.00181	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—epilepsy syndrome	0.000123	0.00179	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—TNF—epilepsy syndrome	0.000123	0.00178	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC1A1—epilepsy syndrome	0.000122	0.00177	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—epilepsy syndrome	0.000121	0.00176	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC6A4—epilepsy syndrome	0.000119	0.00172	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC17A7—epilepsy syndrome	0.000118	0.00171	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC4A10—epilepsy syndrome	0.000118	0.00171	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—HBEGF—epilepsy syndrome	0.000117	0.0017	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—TH—epilepsy syndrome	0.000117	0.00169	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—KCNJ10—epilepsy syndrome	0.000116	0.00168	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GABRA5—epilepsy syndrome	0.000116	0.00168	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—CACNA1A—epilepsy syndrome	0.000116	0.00168	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIA4—epilepsy syndrome	0.000116	0.00168	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—ABAT—epilepsy syndrome	0.000116	0.00168	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—CRH—epilepsy syndrome	0.000115	0.00167	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—SRC—epilepsy syndrome	0.000115	0.00167	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—SLC1A3—epilepsy syndrome	0.000115	0.00167	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GRIK2—epilepsy syndrome	0.000115	0.00167	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC35A3—epilepsy syndrome	0.000114	0.00165	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC35A2—epilepsy syndrome	0.000114	0.00165	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC12A5—epilepsy syndrome	0.000114	0.00165	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CASP3—epilepsy syndrome	0.000112	0.00163	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—ARHGEF9—epilepsy syndrome	0.000111	0.00162	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC17A7—epilepsy syndrome	0.000111	0.00162	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GABRB3—epilepsy syndrome	0.000111	0.00162	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GABRA1—epilepsy syndrome	0.000111	0.00162	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GAD1—epilepsy syndrome	0.00011	0.0016	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—epilepsy syndrome	0.000109	0.00159	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GLUL—epilepsy syndrome	0.000109	0.00158	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC8A1—epilepsy syndrome	0.000109	0.00158	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC2A1—epilepsy syndrome	0.000107	0.00156	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIA2—epilepsy syndrome	0.000107	0.00155	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—TNF—epilepsy syndrome	0.000105	0.00153	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC6A4—epilepsy syndrome	0.000105	0.00153	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—epilepsy syndrome	0.000105	0.00152	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GABBR1—epilepsy syndrome	0.000105	0.00152	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC4A10—epilepsy syndrome	0.000104	0.00151	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC1A2—epilepsy syndrome	0.000103	0.0015	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—CHRNA7—epilepsy syndrome	0.000103	0.0015	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIK1—epilepsy syndrome	0.000103	0.0015	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—COX3—epilepsy syndrome	0.000103	0.00149	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—HMOX1—epilepsy syndrome	0.000103	0.00149	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—epilepsy syndrome	0.000102	0.00149	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GRIN2A—epilepsy syndrome	0.000102	0.00149	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GRIA1—epilepsy syndrome	0.000102	0.00149	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—HBEGF—epilepsy syndrome	0.000101	0.00147	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GABRB2—epilepsy syndrome	9.86e-05	0.00143	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLCO1A2—epilepsy syndrome	9.74e-05	0.00141	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC8A2—epilepsy syndrome	9.74e-05	0.00141	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC9A6—epilepsy syndrome	9.74e-05	0.00141	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GAD2—epilepsy syndrome	9.72e-05	0.00141	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—CHRNB2—epilepsy syndrome	9.68e-05	0.00141	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—AVP—epilepsy syndrome	9.65e-05	0.0014	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC8A1—epilepsy syndrome	9.63e-05	0.0014	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TH—epilepsy syndrome	9.53e-05	0.00138	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC2A1—epilepsy syndrome	9.51e-05	0.00138	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—BDNF—epilepsy syndrome	9.51e-05	0.00138	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—KCNAB2—epilepsy syndrome	9.42e-05	0.00137	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—HTR7—epilepsy syndrome	9.36e-05	0.00136	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—epilepsy syndrome	9.36e-05	0.00136	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—TNF—epilepsy syndrome	9.34e-05	0.00136	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—epilepsy syndrome	9.3e-05	0.00135	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC8A3—epilepsy syndrome	9.29e-05	0.00135	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—GABRG2—epilepsy syndrome	9.29e-05	0.00135	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—KCNMA1—epilepsy syndrome	9.22e-05	0.00134	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HES1—epilepsy syndrome	9.13e-05	0.00133	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—COX3—epilepsy syndrome	9.1e-05	0.00132	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—HBEGF—epilepsy syndrome	8.94e-05	0.0013	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—HMOX1—epilepsy syndrome	8.83e-05	0.00128	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—MEF2C—epilepsy syndrome	8.83e-05	0.00128	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—epilepsy syndrome	8.79e-05	0.00128	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—KCNJ11—epilepsy syndrome	8.79e-05	0.00128	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC1A3—epilepsy syndrome	8.79e-05	0.00128	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIK2—epilepsy syndrome	8.79e-05	0.00128	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC8A2—epilepsy syndrome	8.63e-05	0.00125	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLCO1A2—epilepsy syndrome	8.63e-05	0.00125	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC9A6—epilepsy syndrome	8.63e-05	0.00125	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—YWHAZ—epilepsy syndrome	8.53e-05	0.00124	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—NGF—epilepsy syndrome	8.44e-05	0.00123	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GAD1—epilepsy syndrome	8.43e-05	0.00122	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—NR3C1—epilepsy syndrome	8.4e-05	0.00122	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—epilepsy syndrome	8.29e-05	0.0012	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—GABRG2—epilepsy syndrome	8.23e-05	0.0012	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC8A3—epilepsy syndrome	8.23e-05	0.0012	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GABBR1—epilepsy syndrome	8.04e-05	0.00117	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—epilepsy syndrome	8.03e-05	0.00117	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—AVP—epilepsy syndrome	7.88e-05	0.00114	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIN2A—epilepsy syndrome	7.84e-05	0.00114	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIA1—epilepsy syndrome	7.84e-05	0.00114	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC6A1—epilepsy syndrome	7.84e-05	0.00114	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—HMOX1—epilepsy syndrome	7.82e-05	0.00114	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—BCHE—epilepsy syndrome	7.75e-05	0.00113	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—epilepsy syndrome	7.74e-05	0.00112	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—SIRT1—epilepsy syndrome	7.73e-05	0.00112	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—APOD—epilepsy syndrome	7.57e-05	0.0011	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—DLG4—epilepsy syndrome	7.56e-05	0.0011	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—CHRNB2—epilepsy syndrome	7.42e-05	0.00108	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GRIN2B—epilepsy syndrome	7.39e-05	0.00107	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC1A1—epilepsy syndrome	7.38e-05	0.00107	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC12A2—epilepsy syndrome	7.38e-05	0.00107	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—epilepsy syndrome	7.38e-05	0.00107	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—epilepsy syndrome	7.36e-05	0.00107	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—epilepsy syndrome	7.31e-05	0.00106	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—PLCB1—epilepsy syndrome	7.31e-05	0.00106	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—epilepsy syndrome	7.27e-05	0.00106	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—epilepsy syndrome	7.22e-05	0.00105	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—epilepsy syndrome	7.17e-05	0.00104	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—GABRA5—epilepsy syndrome	7.04e-05	0.00102	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—epilepsy syndrome	6.77e-05	0.000983	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ARHGEF9—epilepsy syndrome	6.75e-05	0.00098	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC17A7—epilepsy syndrome	6.75e-05	0.00098	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—GABRA1—epilepsy syndrome	6.75e-05	0.00098	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—GABRB3—epilepsy syndrome	6.75e-05	0.00098	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—CHRNA4—epilepsy syndrome	6.74e-05	0.000978	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—APOD—epilepsy syndrome	6.71e-05	0.000974	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2D6—epilepsy syndrome	6.56e-05	0.000953	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC1A1—epilepsy syndrome	6.54e-05	0.000949	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC12A2—epilepsy syndrome	6.54e-05	0.000949	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP2D6—epilepsy syndrome	6.47e-05	0.00094	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC1A2—epilepsy syndrome	6.28e-05	0.000911	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—GABRA5—epilepsy syndrome	6.24e-05	0.000906	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—epilepsy syndrome	5.99e-05	0.00087	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—GABRB2—epilepsy syndrome	5.99e-05	0.000869	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ARHGEF9—epilepsy syndrome	5.98e-05	0.000868	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—GABRA1—epilepsy syndrome	5.98e-05	0.000868	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC17A7—epilepsy syndrome	5.98e-05	0.000868	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—GABRB3—epilepsy syndrome	5.98e-05	0.000868	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—CAT—epilepsy syndrome	5.96e-05	0.000865	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—BCHE—epilepsy syndrome	5.94e-05	0.000862	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—epilepsy syndrome	5.93e-05	0.000861	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—AQP1—epilepsy syndrome	5.9e-05	0.000857	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—epilepsy syndrome	5.89e-05	0.000856	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—DLG4—epilepsy syndrome	5.8e-05	0.000842	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TRPV1—epilepsy syndrome	5.74e-05	0.000833	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—NOS2—epilepsy syndrome	5.68e-05	0.000825	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIN2B—epilepsy syndrome	5.67e-05	0.000823	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—PLCB1—epilepsy syndrome	5.6e-05	0.000814	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—epilepsy syndrome	5.56e-05	0.000807	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC8A1—epilepsy syndrome	5.52e-05	0.000802	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—AVP—epilepsy syndrome	5.52e-05	0.000801	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC1A3—epilepsy syndrome	5.34e-05	0.000775	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—AQP4—epilepsy syndrome	5.34e-05	0.000775	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—epilepsy syndrome	5.32e-05	0.000772	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—GABRB2—epilepsy syndrome	5.3e-05	0.00077	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—AQP1—epilepsy syndrome	5.23e-05	0.000759	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCC2—epilepsy syndrome	5.12e-05	0.000743	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TRPV1—epilepsy syndrome	5.08e-05	0.000738	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC8A1—epilepsy syndrome	4.89e-05	0.000711	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—AVP—epilepsy syndrome	4.89e-05	0.00071	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL1B—epilepsy syndrome	4.76e-05	0.000691	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—epilepsy syndrome	4.76e-05	0.000691	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CASP3—epilepsy syndrome	4.75e-05	0.00069	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—AQP4—epilepsy syndrome	4.73e-05	0.000686	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC1A3—epilepsy syndrome	4.73e-05	0.000686	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—JUN—epilepsy syndrome	4.61e-05	0.00067	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCC2—epilepsy syndrome	4.53e-05	0.000658	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—PRKCB—epilepsy syndrome	4.4e-05	0.000639	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	4.35e-05	0.000632	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	4.24e-05	0.000616	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—epilepsy syndrome	4.21e-05	0.000612	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—epilepsy syndrome	4.03e-05	0.000585	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	3.85e-05	0.00056	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—JUN—epilepsy syndrome	3.77e-05	0.000547	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	3.75e-05	0.000545	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	3.6e-05	0.000523	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—TNF—epilepsy syndrome	3.45e-05	0.000502	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	3.44e-05	0.000499	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—PRKCB—epilepsy syndrome	3.37e-05	0.000489	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—ALB—epilepsy syndrome	3.34e-05	0.000485	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—epilepsy syndrome	3.21e-05	0.000467	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	3.19e-05	0.000464	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP2C19—epilepsy syndrome	3.15e-05	0.000457	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP11A1—epilepsy syndrome	3.13e-05	0.000455	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP2C19—epilepsy syndrome	3.11e-05	0.000451	CbGpPWpGaD
Sibutramine—Anorexia—Valproic Acid—epilepsy syndrome	3.1e-05	0.000107	CcSEcCtD
Sibutramine—Tremor—Gabapentin—epilepsy syndrome	3.09e-05	0.000107	CcSEcCtD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP11A1—epilepsy syndrome	3.09e-05	0.000448	CbGpPWpGaD
Sibutramine—Rash—Diazepam—epilepsy syndrome	3.08e-05	0.000107	CcSEcCtD
Sibutramine—Dermatitis—Diazepam—epilepsy syndrome	3.08e-05	0.000107	CcSEcCtD
Sibutramine—Visual impairment—Topiramate—epilepsy syndrome	3.08e-05	0.000107	CcSEcCtD
Sibutramine—Arthralgia—Pregabalin—epilepsy syndrome	3.07e-05	0.000106	CcSEcCtD
Sibutramine—Myalgia—Pregabalin—epilepsy syndrome	3.07e-05	0.000106	CcSEcCtD
Sibutramine—Chest pain—Pregabalin—epilepsy syndrome	3.07e-05	0.000106	CcSEcCtD
Sibutramine—Ill-defined disorder—Gabapentin—epilepsy syndrome	3.06e-05	0.000106	CcSEcCtD
Sibutramine—Dizziness—Zonisamide—epilepsy syndrome	3.06e-05	0.000106	CcSEcCtD
Sibutramine—Headache—Diazepam—epilepsy syndrome	3.06e-05	0.000106	CcSEcCtD
Sibutramine—Anxiety—Pregabalin—epilepsy syndrome	3.06e-05	0.000106	CcSEcCtD
Sibutramine—Diarrhoea—Clonazepam—epilepsy syndrome	3.05e-05	0.000106	CcSEcCtD
Sibutramine—Anaemia—Gabapentin—epilepsy syndrome	3.05e-05	0.000106	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	3.05e-05	0.000442	CbGpPWpGaD
Sibutramine—Hypotension—Valproic Acid—epilepsy syndrome	3.04e-05	0.000105	CcSEcCtD
Sibutramine—Asthenia—Carbamazepine—epilepsy syndrome	3.04e-05	0.000105	CcSEcCtD
Sibutramine—Agitation—Gabapentin—epilepsy syndrome	3.03e-05	0.000105	CcSEcCtD
Sibutramine—Diarrhoea—Phenytoin—epilepsy syndrome	3.03e-05	0.000105	CcSEcCtD
Sibutramine—Discomfort—Pregabalin—epilepsy syndrome	3.03e-05	0.000105	CcSEcCtD
Sibutramine—Nausea—Fosphenytoin—epilepsy syndrome	3.03e-05	0.000105	CcSEcCtD
Sibutramine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	3.02e-05	0.000105	CcSEcCtD
Sibutramine—Angioedema—Gabapentin—epilepsy syndrome	3.02e-05	0.000105	CcSEcCtD
Sibutramine—Hypersensitivity—Lamotrigine—epilepsy syndrome	3.01e-05	0.000104	CcSEcCtD
Sibutramine—Vomiting—Felbamate—epilepsy syndrome	3.01e-05	0.000104	CcSEcCtD
Sibutramine—Dry mouth—Pregabalin—epilepsy syndrome	3e-05	0.000104	CcSEcCtD
Sibutramine—Pruritus—Carbamazepine—epilepsy syndrome	2.99e-05	0.000104	CcSEcCtD
Sibutramine—Rash—Felbamate—epilepsy syndrome	2.98e-05	0.000103	CcSEcCtD
Sibutramine—Eye disorder—Topiramate—epilepsy syndrome	2.98e-05	0.000103	CcSEcCtD
Sibutramine—Dermatitis—Felbamate—epilepsy syndrome	2.98e-05	0.000103	CcSEcCtD
Sibutramine—Malaise—Gabapentin—epilepsy syndrome	2.98e-05	0.000103	CcSEcCtD
Sibutramine—Tinnitus—Topiramate—epilepsy syndrome	2.98e-05	0.000103	CcSEcCtD
Sibutramine—Vertigo—Gabapentin—epilepsy syndrome	2.97e-05	0.000103	CcSEcCtD
Sibutramine—Headache—Felbamate—epilepsy syndrome	2.96e-05	0.000103	CcSEcCtD
Sibutramine—Confusional state—Pregabalin—epilepsy syndrome	2.96e-05	0.000103	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	2.96e-05	0.000103	CcSEcCtD
Sibutramine—Syncope—Gabapentin—epilepsy syndrome	2.96e-05	0.000103	CcSEcCtD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—ALB—epilepsy syndrome	2.96e-05	0.00043	CbGpPWpGaD
Sibutramine—Leukopenia—Gabapentin—epilepsy syndrome	2.96e-05	0.000102	CcSEcCtD
Sibutramine—Dizziness—Clonazepam—epilepsy syndrome	2.95e-05	0.000102	CcSEcCtD
Sibutramine—Nausea—Vigabatrin—epilepsy syndrome	2.95e-05	0.000102	CcSEcCtD
Sibutramine—Vomiting—Zonisamide—epilepsy syndrome	2.95e-05	0.000102	CcSEcCtD
Sibutramine—Insomnia—Valproic Acid—epilepsy syndrome	2.94e-05	0.000102	CcSEcCtD
Sibutramine—Oedema—Pregabalin—epilepsy syndrome	2.94e-05	0.000102	CcSEcCtD
Sibutramine—Anaphylactic shock—Pregabalin—epilepsy syndrome	2.94e-05	0.000102	CcSEcCtD
Sibutramine—Asthenia—Lamotrigine—epilepsy syndrome	2.94e-05	0.000102	CcSEcCtD
Sibutramine—Dizziness—Phenytoin—epilepsy syndrome	2.93e-05	0.000102	CcSEcCtD
Sibutramine—Rash—Zonisamide—epilepsy syndrome	2.92e-05	0.000101	CcSEcCtD
Sibutramine—Infection—Pregabalin—epilepsy syndrome	2.92e-05	0.000101	CcSEcCtD
Sibutramine—Paraesthesia—Valproic Acid—epilepsy syndrome	2.92e-05	0.000101	CcSEcCtD
Sibutramine—Palpitations—Gabapentin—epilepsy syndrome	2.92e-05	0.000101	CcSEcCtD
Sibutramine—Dermatitis—Zonisamide—epilepsy syndrome	2.92e-05	0.000101	CcSEcCtD
Sibutramine—Dizziness—Oxcarbazepine—epilepsy syndrome	2.92e-05	0.000101	CcSEcCtD
Sibutramine—Nausea—Diazepam—epilepsy syndrome	2.9e-05	0.000101	CcSEcCtD
Sibutramine—Loss of consciousness—Gabapentin—epilepsy syndrome	2.9e-05	0.000101	CcSEcCtD
Sibutramine—Headache—Zonisamide—epilepsy syndrome	2.9e-05	0.000101	CcSEcCtD
Sibutramine—Dyspnoea—Valproic Acid—epilepsy syndrome	2.9e-05	0.0001	CcSEcCtD
Sibutramine—Diarrhoea—Carbamazepine—epilepsy syndrome	2.9e-05	0.0001	CcSEcCtD
Sibutramine—Angiopathy—Topiramate—epilepsy syndrome	2.9e-05	0.0001	CcSEcCtD
Sibutramine—Pruritus—Lamotrigine—epilepsy syndrome	2.89e-05	0.0001	CcSEcCtD
Sibutramine—Shock—Pregabalin—epilepsy syndrome	2.89e-05	0.0001	CcSEcCtD
Sibutramine—Somnolence—Valproic Acid—epilepsy syndrome	2.89e-05	0.0001	CcSEcCtD
Sibutramine—Immune system disorder—Topiramate—epilepsy syndrome	2.88e-05	9.99e-05	CcSEcCtD
Sibutramine—Cough—Gabapentin—epilepsy syndrome	2.88e-05	9.99e-05	CcSEcCtD
Sibutramine—Thrombocytopenia—Pregabalin—epilepsy syndrome	2.88e-05	9.98e-05	CcSEcCtD
Sibutramine—Tachycardia—Pregabalin—epilepsy syndrome	2.87e-05	9.94e-05	CcSEcCtD
Sibutramine—Chills—Topiramate—epilepsy syndrome	2.86e-05	9.93e-05	CcSEcCtD
Sibutramine—Dyspepsia—Valproic Acid—epilepsy syndrome	2.86e-05	9.92e-05	CcSEcCtD
Sibutramine—Convulsion—Gabapentin—epilepsy syndrome	2.86e-05	9.92e-05	CcSEcCtD
Sibutramine—Skin disorder—Pregabalin—epilepsy syndrome	2.85e-05	9.9e-05	CcSEcCtD
Sibutramine—Hypertension—Gabapentin—epilepsy syndrome	2.85e-05	9.88e-05	CcSEcCtD
Sibutramine—Hyperhidrosis—Pregabalin—epilepsy syndrome	2.84e-05	9.85e-05	CcSEcCtD
Sibutramine—Vomiting—Clonazepam—epilepsy syndrome	2.84e-05	9.84e-05	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	2.83e-05	0.000411	CbGpPWpGaD
Sibutramine—Decreased appetite—Valproic Acid—epilepsy syndrome	2.83e-05	9.8e-05	CcSEcCtD
Sibutramine—CYP3A4—Biological oxidations—CYP2D6—epilepsy syndrome	2.82e-05	0.00041	CbGpPWpGaD
Sibutramine—Alopecia—Topiramate—epilepsy syndrome	2.82e-05	9.78e-05	CcSEcCtD
Sibutramine—Vomiting—Phenytoin—epilepsy syndrome	2.82e-05	9.77e-05	CcSEcCtD
Sibutramine—Rash—Clonazepam—epilepsy syndrome	2.81e-05	9.76e-05	CcSEcCtD
Sibutramine—Dermatitis—Clonazepam—epilepsy syndrome	2.81e-05	9.75e-05	CcSEcCtD
Sibutramine—Chest pain—Gabapentin—epilepsy syndrome	2.81e-05	9.75e-05	CcSEcCtD
Sibutramine—Arthralgia—Gabapentin—epilepsy syndrome	2.81e-05	9.75e-05	CcSEcCtD
Sibutramine—Myalgia—Gabapentin—epilepsy syndrome	2.81e-05	9.75e-05	CcSEcCtD
Sibutramine—Nausea—Felbamate—epilepsy syndrome	2.81e-05	9.75e-05	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	2.81e-05	9.73e-05	CcSEcCtD
Sibutramine—Vomiting—Oxcarbazepine—epilepsy syndrome	2.8e-05	9.72e-05	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—AVP—epilepsy syndrome	2.8e-05	0.000407	CbGpPWpGaD
Sibutramine—Anxiety—Gabapentin—epilepsy syndrome	2.8e-05	9.71e-05	CcSEcCtD
Sibutramine—Anorexia—Pregabalin—epilepsy syndrome	2.8e-05	9.71e-05	CcSEcCtD
Sibutramine—Dizziness—Carbamazepine—epilepsy syndrome	2.8e-05	9.7e-05	CcSEcCtD
Sibutramine—Diarrhoea—Lamotrigine—epilepsy syndrome	2.8e-05	9.7e-05	CcSEcCtD
Sibutramine—Headache—Clonazepam—epilepsy syndrome	2.8e-05	9.7e-05	CcSEcCtD
Sibutramine—Rash—Phenytoin—epilepsy syndrome	2.8e-05	9.69e-05	CcSEcCtD
Sibutramine—Dermatitis—Phenytoin—epilepsy syndrome	2.79e-05	9.68e-05	CcSEcCtD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP2D6—epilepsy syndrome	2.79e-05	0.000405	CbGpPWpGaD
Sibutramine—Rash—Oxcarbazepine—epilepsy syndrome	2.78e-05	9.64e-05	CcSEcCtD
Sibutramine—Pain—Valproic Acid—epilepsy syndrome	2.78e-05	9.64e-05	CcSEcCtD
Sibutramine—Constipation—Valproic Acid—epilepsy syndrome	2.78e-05	9.64e-05	CcSEcCtD
Sibutramine—Dermatitis—Oxcarbazepine—epilepsy syndrome	2.78e-05	9.63e-05	CcSEcCtD
Sibutramine—Headache—Phenytoin—epilepsy syndrome	2.78e-05	9.63e-05	CcSEcCtD
Sibutramine—Malnutrition—Topiramate—epilepsy syndrome	2.78e-05	9.63e-05	CcSEcCtD
Sibutramine—Discomfort—Gabapentin—epilepsy syndrome	2.78e-05	9.63e-05	CcSEcCtD
Sibutramine—Headache—Oxcarbazepine—epilepsy syndrome	2.76e-05	9.58e-05	CcSEcCtD
Sibutramine—Nausea—Zonisamide—epilepsy syndrome	2.75e-05	9.54e-05	CcSEcCtD
Sibutramine—Dry mouth—Gabapentin—epilepsy syndrome	2.75e-05	9.53e-05	CcSEcCtD
Sibutramine—Hypotension—Pregabalin—epilepsy syndrome	2.75e-05	9.52e-05	CcSEcCtD
Sibutramine—Flatulence—Topiramate—epilepsy syndrome	2.74e-05	9.49e-05	CcSEcCtD
Sibutramine—Tension—Topiramate—epilepsy syndrome	2.73e-05	9.45e-05	CcSEcCtD
Sibutramine—Dysgeusia—Topiramate—epilepsy syndrome	2.72e-05	9.43e-05	CcSEcCtD
Sibutramine—Confusional state—Gabapentin—epilepsy syndrome	2.72e-05	9.42e-05	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	2.71e-05	0.000394	CbGpPWpGaD
Sibutramine—Dizziness—Lamotrigine—epilepsy syndrome	2.71e-05	9.38e-05	CcSEcCtD
Sibutramine—Nervousness—Topiramate—epilepsy syndrome	2.7e-05	9.35e-05	CcSEcCtD
Sibutramine—Anaphylactic shock—Gabapentin—epilepsy syndrome	2.69e-05	9.34e-05	CcSEcCtD
Sibutramine—Oedema—Gabapentin—epilepsy syndrome	2.69e-05	9.34e-05	CcSEcCtD
Sibutramine—Vomiting—Carbamazepine—epilepsy syndrome	2.69e-05	9.33e-05	CcSEcCtD
Sibutramine—Back pain—Topiramate—epilepsy syndrome	2.69e-05	9.32e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Valproic Acid—epilepsy syndrome	2.68e-05	9.29e-05	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	2.68e-05	9.28e-05	CcSEcCtD
Sibutramine—Infection—Gabapentin—epilepsy syndrome	2.68e-05	9.28e-05	CcSEcCtD
Sibutramine—Muscle spasms—Topiramate—epilepsy syndrome	2.67e-05	9.26e-05	CcSEcCtD
Sibutramine—Rash—Carbamazepine—epilepsy syndrome	2.67e-05	9.25e-05	CcSEcCtD
Sibutramine—Dermatitis—Carbamazepine—epilepsy syndrome	2.67e-05	9.24e-05	CcSEcCtD
Sibutramine—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	2.66e-05	9.22e-05	CcSEcCtD
Sibutramine—Insomnia—Pregabalin—epilepsy syndrome	2.66e-05	9.22e-05	CcSEcCtD
Sibutramine—Nausea—Clonazepam—epilepsy syndrome	2.65e-05	9.19e-05	CcSEcCtD
Sibutramine—Headache—Carbamazepine—epilepsy syndrome	2.65e-05	9.19e-05	CcSEcCtD
Sibutramine—Shock—Gabapentin—epilepsy syndrome	2.65e-05	9.19e-05	CcSEcCtD
Sibutramine—Paraesthesia—Pregabalin—epilepsy syndrome	2.64e-05	9.15e-05	CcSEcCtD
Sibutramine—Thrombocytopenia—Gabapentin—epilepsy syndrome	2.64e-05	9.15e-05	CcSEcCtD
Sibutramine—Nausea—Phenytoin—epilepsy syndrome	2.63e-05	9.13e-05	CcSEcCtD
Sibutramine—Tachycardia—Gabapentin—epilepsy syndrome	2.63e-05	9.12e-05	CcSEcCtD
Sibutramine—Dyspnoea—Pregabalin—epilepsy syndrome	2.62e-05	9.08e-05	CcSEcCtD
Sibutramine—Nausea—Oxcarbazepine—epilepsy syndrome	2.62e-05	9.08e-05	CcSEcCtD
Sibutramine—Vision blurred—Topiramate—epilepsy syndrome	2.62e-05	9.08e-05	CcSEcCtD
Sibutramine—Skin disorder—Gabapentin—epilepsy syndrome	2.62e-05	9.08e-05	CcSEcCtD
Sibutramine—Somnolence—Pregabalin—epilepsy syndrome	2.61e-05	9.06e-05	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—epilepsy syndrome	2.61e-05	0.000378	CbGpPWpGaD
Sibutramine—Hyperhidrosis—Gabapentin—epilepsy syndrome	2.61e-05	9.03e-05	CcSEcCtD
Sibutramine—Tremor—Topiramate—epilepsy syndrome	2.6e-05	9.02e-05	CcSEcCtD
Sibutramine—Vomiting—Lamotrigine—epilepsy syndrome	2.6e-05	9.02e-05	CcSEcCtD
Sibutramine—Urticaria—Valproic Acid—epilepsy syndrome	2.58e-05	8.95e-05	CcSEcCtD
Sibutramine—Rash—Lamotrigine—epilepsy syndrome	2.58e-05	8.94e-05	CcSEcCtD
Sibutramine—Ill-defined disorder—Topiramate—epilepsy syndrome	2.58e-05	8.94e-05	CcSEcCtD
Sibutramine—Dermatitis—Lamotrigine—epilepsy syndrome	2.58e-05	8.93e-05	CcSEcCtD
Sibutramine—Abdominal pain—Valproic Acid—epilepsy syndrome	2.57e-05	8.91e-05	CcSEcCtD
Sibutramine—Body temperature increased—Valproic Acid—epilepsy syndrome	2.57e-05	8.91e-05	CcSEcCtD
Sibutramine—Anorexia—Gabapentin—epilepsy syndrome	2.57e-05	8.91e-05	CcSEcCtD
Sibutramine—Anaemia—Topiramate—epilepsy syndrome	2.57e-05	8.9e-05	CcSEcCtD
Sibutramine—Headache—Lamotrigine—epilepsy syndrome	2.56e-05	8.89e-05	CcSEcCtD
Sibutramine—Decreased appetite—Pregabalin—epilepsy syndrome	2.55e-05	8.86e-05	CcSEcCtD
Sibutramine—Agitation—Topiramate—epilepsy syndrome	2.55e-05	8.85e-05	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	2.54e-05	8.8e-05	CcSEcCtD
Sibutramine—Hypotension—Gabapentin—epilepsy syndrome	2.52e-05	8.73e-05	CcSEcCtD
Sibutramine—Nausea—Carbamazepine—epilepsy syndrome	2.51e-05	8.72e-05	CcSEcCtD
Sibutramine—Pain—Pregabalin—epilepsy syndrome	2.51e-05	8.71e-05	CcSEcCtD
Sibutramine—Constipation—Pregabalin—epilepsy syndrome	2.51e-05	8.71e-05	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	2.51e-05	0.000364	CbGpPWpGaD
Sibutramine—Malaise—Topiramate—epilepsy syndrome	2.51e-05	8.69e-05	CcSEcCtD
Sibutramine—Vertigo—Topiramate—epilepsy syndrome	2.5e-05	8.65e-05	CcSEcCtD
Sibutramine—Syncope—Topiramate—epilepsy syndrome	2.49e-05	8.64e-05	CcSEcCtD
Sibutramine—Leukopenia—Topiramate—epilepsy syndrome	2.49e-05	8.62e-05	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—AVP—epilepsy syndrome	2.48e-05	0.000361	CbGpPWpGaD
Sibutramine—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	2.46e-05	8.51e-05	CcSEcCtD
Sibutramine—Palpitations—Topiramate—epilepsy syndrome	2.46e-05	8.51e-05	CcSEcCtD
Sibutramine—Loss of consciousness—Topiramate—epilepsy syndrome	2.44e-05	8.47e-05	CcSEcCtD
Sibutramine—Insomnia—Gabapentin—epilepsy syndrome	2.44e-05	8.45e-05	CcSEcCtD
Sibutramine—Nausea—Lamotrigine—epilepsy syndrome	2.43e-05	8.42e-05	CcSEcCtD
Sibutramine—Cough—Topiramate—epilepsy syndrome	2.42e-05	8.4e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Pregabalin—epilepsy syndrome	2.42e-05	8.4e-05	CcSEcCtD
Sibutramine—Paraesthesia—Gabapentin—epilepsy syndrome	2.42e-05	8.39e-05	CcSEcCtD
Sibutramine—Convulsion—Topiramate—epilepsy syndrome	2.41e-05	8.34e-05	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	2.4e-05	0.000349	CbGpPWpGaD
Sibutramine—Gastrointestinal pain—Pregabalin—epilepsy syndrome	2.4e-05	8.33e-05	CcSEcCtD
Sibutramine—Dyspnoea—Gabapentin—epilepsy syndrome	2.4e-05	8.33e-05	CcSEcCtD
Sibutramine—Hypertension—Topiramate—epilepsy syndrome	2.4e-05	8.32e-05	CcSEcCtD
Sibutramine—Somnolence—Gabapentin—epilepsy syndrome	2.4e-05	8.31e-05	CcSEcCtD
Sibutramine—Hypersensitivity—Valproic Acid—epilepsy syndrome	2.4e-05	8.3e-05	CcSEcCtD
Sibutramine—Dyspepsia—Gabapentin—epilepsy syndrome	2.37e-05	8.22e-05	CcSEcCtD
Sibutramine—Chest pain—Topiramate—epilepsy syndrome	2.37e-05	8.2e-05	CcSEcCtD
Sibutramine—Arthralgia—Topiramate—epilepsy syndrome	2.37e-05	8.2e-05	CcSEcCtD
Sibutramine—Myalgia—Topiramate—epilepsy syndrome	2.37e-05	8.2e-05	CcSEcCtD
Sibutramine—Anxiety—Topiramate—epilepsy syndrome	2.36e-05	8.17e-05	CcSEcCtD
Sibutramine—Decreased appetite—Gabapentin—epilepsy syndrome	2.34e-05	8.12e-05	CcSEcCtD
Sibutramine—Discomfort—Topiramate—epilepsy syndrome	2.34e-05	8.1e-05	CcSEcCtD
Sibutramine—Urticaria—Pregabalin—epilepsy syndrome	2.33e-05	8.09e-05	CcSEcCtD
Sibutramine—Asthenia—Valproic Acid—epilepsy syndrome	2.33e-05	8.09e-05	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	2.33e-05	8.07e-05	CcSEcCtD
Sibutramine—Abdominal pain—Pregabalin—epilepsy syndrome	2.32e-05	8.05e-05	CcSEcCtD
Sibutramine—Body temperature increased—Pregabalin—epilepsy syndrome	2.32e-05	8.05e-05	CcSEcCtD
Sibutramine—Dry mouth—Topiramate—epilepsy syndrome	2.31e-05	8.02e-05	CcSEcCtD
Sibutramine—Pain—Gabapentin—epilepsy syndrome	2.3e-05	7.99e-05	CcSEcCtD
Sibutramine—Constipation—Gabapentin—epilepsy syndrome	2.3e-05	7.99e-05	CcSEcCtD
Sibutramine—Pruritus—Valproic Acid—epilepsy syndrome	2.3e-05	7.97e-05	CcSEcCtD
Sibutramine—Confusional state—Topiramate—epilepsy syndrome	2.29e-05	7.93e-05	CcSEcCtD
Sibutramine—Oedema—Topiramate—epilepsy syndrome	2.27e-05	7.86e-05	CcSEcCtD
Sibutramine—Infection—Topiramate—epilepsy syndrome	2.25e-05	7.81e-05	CcSEcCtD
Sibutramine—Shock—Topiramate—epilepsy syndrome	2.23e-05	7.73e-05	CcSEcCtD
Sibutramine—Diarrhoea—Valproic Acid—epilepsy syndrome	2.22e-05	7.71e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Gabapentin—epilepsy syndrome	2.22e-05	7.7e-05	CcSEcCtD
Sibutramine—Thrombocytopenia—Topiramate—epilepsy syndrome	2.22e-05	7.7e-05	CcSEcCtD
Sibutramine—Tachycardia—Topiramate—epilepsy syndrome	2.21e-05	7.67e-05	CcSEcCtD
Sibutramine—Gastrointestinal pain—Gabapentin—epilepsy syndrome	2.2e-05	7.64e-05	CcSEcCtD
Sibutramine—Skin disorder—Topiramate—epilepsy syndrome	2.2e-05	7.63e-05	CcSEcCtD
Sibutramine—Hyperhidrosis—Topiramate—epilepsy syndrome	2.19e-05	7.6e-05	CcSEcCtD
Sibutramine—Hypersensitivity—Pregabalin—epilepsy syndrome	2.17e-05	7.51e-05	CcSEcCtD
Sibutramine—Anorexia—Topiramate—epilepsy syndrome	2.16e-05	7.49e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—CA13—epilepsy syndrome	2.15e-05	0.000313	CbGpPWpGaD
Sibutramine—Dizziness—Valproic Acid—epilepsy syndrome	2.15e-05	7.45e-05	CcSEcCtD
Sibutramine—Urticaria—Gabapentin—epilepsy syndrome	2.14e-05	7.42e-05	CcSEcCtD
Sibutramine—Body temperature increased—Gabapentin—epilepsy syndrome	2.13e-05	7.39e-05	CcSEcCtD
Sibutramine—Abdominal pain—Gabapentin—epilepsy syndrome	2.13e-05	7.39e-05	CcSEcCtD
Sibutramine—Hypotension—Topiramate—epilepsy syndrome	2.12e-05	7.34e-05	CcSEcCtD
Sibutramine—Asthenia—Pregabalin—epilepsy syndrome	2.11e-05	7.31e-05	CcSEcCtD
Sibutramine—Pruritus—Pregabalin—epilepsy syndrome	2.08e-05	7.21e-05	CcSEcCtD
Sibutramine—Vomiting—Valproic Acid—epilepsy syndrome	2.07e-05	7.17e-05	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	2.07e-05	7.16e-05	CcSEcCtD
Sibutramine—Insomnia—Topiramate—epilepsy syndrome	2.05e-05	7.11e-05	CcSEcCtD
Sibutramine—Rash—Valproic Acid—epilepsy syndrome	2.05e-05	7.11e-05	CcSEcCtD
Sibutramine—Dermatitis—Valproic Acid—epilepsy syndrome	2.05e-05	7.1e-05	CcSEcCtD
Sibutramine—Headache—Valproic Acid—epilepsy syndrome	2.04e-05	7.06e-05	CcSEcCtD
Sibutramine—Paraesthesia—Topiramate—epilepsy syndrome	2.04e-05	7.06e-05	CcSEcCtD
Sibutramine—Dyspnoea—Topiramate—epilepsy syndrome	2.02e-05	7.01e-05	CcSEcCtD
Sibutramine—Somnolence—Topiramate—epilepsy syndrome	2.02e-05	6.99e-05	CcSEcCtD
Sibutramine—Diarrhoea—Pregabalin—epilepsy syndrome	2.01e-05	6.97e-05	CcSEcCtD
Sibutramine—Dyspepsia—Topiramate—epilepsy syndrome	2e-05	6.92e-05	CcSEcCtD
Sibutramine—Hypersensitivity—Gabapentin—epilepsy syndrome	1.99e-05	6.88e-05	CcSEcCtD
Sibutramine—Decreased appetite—Topiramate—epilepsy syndrome	1.97e-05	6.83e-05	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.96e-05	6.79e-05	CcSEcCtD
Sibutramine—Dizziness—Pregabalin—epilepsy syndrome	1.94e-05	6.74e-05	CcSEcCtD
Sibutramine—Pain—Topiramate—epilepsy syndrome	1.94e-05	6.72e-05	CcSEcCtD
Sibutramine—Constipation—Topiramate—epilepsy syndrome	1.94e-05	6.72e-05	CcSEcCtD
Sibutramine—Asthenia—Gabapentin—epilepsy syndrome	1.93e-05	6.7e-05	CcSEcCtD
Sibutramine—Nausea—Valproic Acid—epilepsy syndrome	1.93e-05	6.69e-05	CcSEcCtD
Sibutramine—Pruritus—Gabapentin—epilepsy syndrome	1.91e-05	6.61e-05	CcSEcCtD
Sibutramine—Vomiting—Pregabalin—epilepsy syndrome	1.87e-05	6.48e-05	CcSEcCtD
Sibutramine—Feeling abnormal—Topiramate—epilepsy syndrome	1.87e-05	6.48e-05	CcSEcCtD
Sibutramine—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.85e-05	6.43e-05	CcSEcCtD
Sibutramine—Rash—Pregabalin—epilepsy syndrome	1.85e-05	6.42e-05	CcSEcCtD
Sibutramine—Dermatitis—Pregabalin—epilepsy syndrome	1.85e-05	6.42e-05	CcSEcCtD
Sibutramine—Diarrhoea—Gabapentin—epilepsy syndrome	1.84e-05	6.39e-05	CcSEcCtD
Sibutramine—Headache—Pregabalin—epilepsy syndrome	1.84e-05	6.38e-05	CcSEcCtD
Sibutramine—Urticaria—Topiramate—epilepsy syndrome	1.8e-05	6.24e-05	CcSEcCtD
Sibutramine—Body temperature increased—Topiramate—epilepsy syndrome	1.79e-05	6.21e-05	CcSEcCtD
Sibutramine—Abdominal pain—Topiramate—epilepsy syndrome	1.79e-05	6.21e-05	CcSEcCtD
Sibutramine—Dizziness—Gabapentin—epilepsy syndrome	1.78e-05	6.18e-05	CcSEcCtD
Sibutramine—Nausea—Pregabalin—epilepsy syndrome	1.75e-05	6.05e-05	CcSEcCtD
Sibutramine—Vomiting—Gabapentin—epilepsy syndrome	1.71e-05	5.94e-05	CcSEcCtD
Sibutramine—Rash—Gabapentin—epilepsy syndrome	1.7e-05	5.89e-05	CcSEcCtD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.7e-05	0.000247	CbGpPWpGaD
Sibutramine—Dermatitis—Gabapentin—epilepsy syndrome	1.7e-05	5.89e-05	CcSEcCtD
Sibutramine—Headache—Gabapentin—epilepsy syndrome	1.69e-05	5.85e-05	CcSEcCtD
Sibutramine—Hypersensitivity—Topiramate—epilepsy syndrome	1.67e-05	5.79e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—GLUD1—epilepsy syndrome	1.63e-05	0.000237	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ADK—epilepsy syndrome	1.63e-05	0.000237	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PDXK—epilepsy syndrome	1.63e-05	0.000237	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CERS1—epilepsy syndrome	1.63e-05	0.000237	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—FAR1—epilepsy syndrome	1.63e-05	0.000237	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—L2HGDH—epilepsy syndrome	1.63e-05	0.000237	CbGpPWpGaD
Sibutramine—Asthenia—Topiramate—epilepsy syndrome	1.63e-05	5.64e-05	CcSEcCtD
Sibutramine—Pruritus—Topiramate—epilepsy syndrome	1.6e-05	5.56e-05	CcSEcCtD
Sibutramine—Nausea—Gabapentin—epilepsy syndrome	1.6e-05	5.55e-05	CcSEcCtD
Sibutramine—Diarrhoea—Topiramate—epilepsy syndrome	1.55e-05	5.38e-05	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.5e-05	0.000218	CbGpPWpGaD
Sibutramine—Dizziness—Topiramate—epilepsy syndrome	1.5e-05	5.2e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—PNPO—epilepsy syndrome	1.49e-05	0.000217	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NHLRC1—epilepsy syndrome	1.49e-05	0.000217	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GAMT—epilepsy syndrome	1.49e-05	0.000217	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—EPM2A—epilepsy syndrome	1.49e-05	0.000217	CbGpPWpGaD
Sibutramine—Vomiting—Topiramate—epilepsy syndrome	1.44e-05	5e-05	CcSEcCtD
Sibutramine—Rash—Topiramate—epilepsy syndrome	1.43e-05	4.96e-05	CcSEcCtD
Sibutramine—Dermatitis—Topiramate—epilepsy syndrome	1.43e-05	4.95e-05	CcSEcCtD
Sibutramine—Headache—Topiramate—epilepsy syndrome	1.42e-05	4.92e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—CA4—epilepsy syndrome	1.39e-05	0.000202	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—QDPR—epilepsy syndrome	1.39e-05	0.000202	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—POMC—epilepsy syndrome	1.38e-05	0.000201	CbGpPWpGaD
Sibutramine—Nausea—Topiramate—epilepsy syndrome	1.35e-05	4.67e-05	CcSEcCtD
Sibutramine—CYP3A4—Metabolism—COX3—epilepsy syndrome	1.31e-05	0.00019	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	1.24e-05	0.00018	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	1.24e-05	0.00018	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	1.24e-05	0.00018	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PFKL—epilepsy syndrome	1.24e-05	0.00018	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	1.24e-05	0.00018	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—UPB1—epilepsy syndrome	1.13e-05	0.000164	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NEU1—epilepsy syndrome	1.13e-05	0.000164	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ATIC—epilepsy syndrome	1.13e-05	0.000164	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	1.09e-05	0.000158	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GBE1—epilepsy syndrome	1.05e-05	0.000153	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	1.05e-05	0.000153	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	9.89e-06	0.000144	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	9.62e-06	0.00014	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NT5E—epilepsy syndrome	9.38e-06	0.000136	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALAD—epilepsy syndrome	9.38e-06	0.000136	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	8.95e-06	0.00013	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	8.95e-06	0.00013	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	8.75e-06	0.000127	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ADSL—epilepsy syndrome	8.58e-06	0.000125	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GLUL—epilepsy syndrome	8.41e-06	0.000122	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	8.26e-06	0.00012	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	7.72e-06	0.000112	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AQP1—epilepsy syndrome	7.5e-06	0.000109	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	6.78e-06	9.85e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	6.78e-06	9.85e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	5.53e-06	8.03e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	5.39e-06	7.82e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	5.35e-06	7.77e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	4.83e-06	7.02e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	4.6e-06	6.68e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—BCHE—epilepsy syndrome	4.58e-06	6.65e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	4.37e-06	6.34e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	4.32e-06	6.28e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—TH—epilepsy syndrome	4.31e-06	6.25e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	3.59e-06	5.22e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CAT—epilepsy syndrome	3.55e-06	5.15e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	3.45e-06	5.01e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GPX1—epilepsy syndrome	3.21e-06	4.66e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AGT—epilepsy syndrome	2.81e-06	4.08e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—APOE—epilepsy syndrome	2.76e-06	4e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—POMC—epilepsy syndrome	2.37e-06	3.44e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALB—epilepsy syndrome	2.16e-06	3.13e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	1.89e-06	2.74e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AKT1—epilepsy syndrome	9.49e-07	1.38e-05	CbGpPWpGaD
